Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1
Phase 1
- Conditions
- Methamphetamine Dependence
- Registration Number
- NCT00519259
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- Must be able to provide written informed consent
- Must have a body mass index between 18 and 30
- Have no medical contraindications as determined by medical history, physical exam, ECG, hematology and blood chemistry profile, and urinalysis
- Must have a negative drug test at screening and admission
- If female of child bearing potential, must agree to use birth control
Exclusion Criteria
- Please contact the site for more information
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Tolerability
- Secondary Outcome Measures
Name Time Method Safety Pharmacokinetic parameters Cardiovascular responses Psychological effects of lobeline
Trial Locations
- Locations (1)
Langley Porter Psychiatric Institute
🇺🇸San Francisco, California, United States